Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.67 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.67 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.50 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.50 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.50 |
| ▸ | OPRM1 | P35372 | 9/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | PRCP | P42785 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32689446 | 1.00 | TSHR (0.67) | TSHRNPSR1HDAC4HDAC7HDAC5 | |
| SCHEMBL13646900 | 0.86 | TSHR (0.65) | TSHRNPSR1OPRM1SLC6A2SLC6A4 | |
| SCHEMBL11104021 | 0.83 | TSHR (0.66) | TSHRNPSR1OPRM1SLC6A2SLC6A4 | |
| SCHEMBL4022286 | 0.83 | TSHR (0.75) | TSHRNPSR1OPRM1SLC6A2SLC6A4 | |
| SCHEMBL6204050 | 0.82 | TSHR (0.60) | TSHRNPSR1OPRM1SLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL11481488 | 0.82 | TSHR (0.68) | TSHRNPSR1OPRM1SLC6A2SLC6A4 | |
| SCHEMBL28134799 | 0.82 | TSHR (0.60) | TSHRNPSR1OPRM1SLC6A2SLC6A4 | |
| SCHEMBL19960906 | 0.82 | TSHR (0.60) | TSHRNPSR1OPRM1SLC6A2SLC6A4 | |
| 1,2,3,4-Tetrahydroisoquinoline SCHEMBL1027366 | 0.82 | PNMT (0.50) | TSHRNPSR1HDAC4HDAC7HDAC5 | |
| SCHEMBL514422 | 0.81 | TSHR (0.97) | TSHRNPSR1OPRM1SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-121715260-A | Tetrahydroisoquinoline hydroxamic acid collecting agent and preparation method thereof | 天津天宝翔科技股份有限公司 | 2026-03-24 | — | — | CN | disclosed |
| CN-101668746-A | As histamine H3Tetrahydroisoquinoline compounds as receptor modulators | JANSSEN PHARMACEUTICA NV | 2010-03-10 | — | — | CN | disclosed |
| US-20070203118-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINES USED IN THE FORM OF MMP INHIBITORS, METHOD FOR THE PRODUCTION AND USE THEREOF IN THE FORM OF DRUGS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-08-30 | — | — | US | disclosed |
| CN-101006059-A | Substituted tetrahydroisoquinolines for use as MMP inhibitors, method for the production thereof, and use thereof in the form of medicaments | SANOFI AVENTIS DEUTSCHLAND (DE) | 2007-07-25 | — | — | CN | disclosed |
| EP-1763516-A2 | SUBSTITUTED TETRAHYDROISOCHINOLINES USED IN THE FORM OF MMP INHIBITORS, METHOD FOR THE PRODUCTION AND USE THEREOF IN THE FORM OF DRAGS | Sanofi-Aventis Deutschland GmbH (DE) | 2007-03-21 | — | — | EP | disclosed |
| WO-2006002763-A2 | SUBSTITUTED TETRAHYDROISOCHINOLINES USED IN THE FORM OF MMP INHIBITORS, METHOD FOR THE PRODUCTION AND USE THEREOF IN THE FORM OF DRAGS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2006-01-12 | — | — | WO | disclosed |
| CN-1187332-C | Tetrahydroisoquinoline hydroximic acid sulfamide compound, its synthesis method and its application | SHANGHAI INST ORGANIC CHEM (CN) | 2005-02-02 | — | — | CN | disclosed |
| CN-1380288-A | Tetrahydroisoquinoline hydroximic acid sulfamide compound, its synthesis method and its application | SHANGHAI INST ORGANIC CHEM (CN) | 2002-11-20 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203118-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINES USED IN THE FORM OF MMP INHIBITORS, METHOD FOR THE PRODUCTION AND USE THEREOF IN THE FORM OF DRUGS | MMP9, MMP2, MMP3 | TSHR 3422/4885NPSR1 1066/4885HDAC4 358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.